Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Janpix and Critical Pressure.
Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss:MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ:VSAR).
Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder. Francesco also serves on the strategic advisory board of the University of Geneva.